# Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

> **NCT04183712** · PHASE2 · RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 102 (estimated)

## Conditions studied

- Gallbladder Carcinoma

## Interventions

- **DRUG:** gemcitabine and oxaliplatin.
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT04183712
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-01
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183712, "Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04183712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*